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ABSTRACT 
In the framework of the nitroimidazole interlaboratory study 03/01, organised by BGW Berlin in 
its position as Community Reference Laboratory (CRD, four muscle samples were screened for 
the presence of dimetridazole (DMZ), ronidazole (RNZ), metronidazole (MNZ) and the hydroxy-
metabolite of DMZ and RNZ: 2-hydroxymethyl-l-methyl-5-nitroimidazole (HMMNI). 
The screening was carried out with HPLC-UV and resulted in a limit of detection of 0.5 ug/kg for 
all analytes. Three samples were suspected to contain HMMNI and/or MNZ and DMZ. 
After screening, the results were confirmed by LC-MS/MS. The confirmatory analysis was also 
used for quantification of the amounts present. The results of the screening analyses could be 
confirmed with the exception of DMZ in sample 2001_521. The confirmatory analysis also 
indicated the presence of DMZ in a very small amount in this sample, but confirmation could not 
be achieved according to EU criteria. 
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SAMENVATTING 
Interlaboratorium studie nitroimidazolen 03/01 
Rapport 2001.023 Juni 2001 
B.J.A. Berendsen en J.A. van Rhijn 
Rijks-Kwaliteitsinstituut voor land- en tuinbouwprodukten (RIKILT) 
Bornsesteeg 45, 6708 PD Wageningen 
Postbus 230, 6700 AE Wageningen 
6 bijlagen, 2 referenties 
In het kader van de nitroimidazole interlaboratorium studie 03/01, georganiseerd door BGW 
Berlijn in haar bevoegdheid als Communautair Referentie Laboratorium (CRL), zijn vier 
vleesmonsters gescreend op de aanwezigheid van dimetridazole (DMZ), ronidazole (RNZ), 
metronidazole (MNZ) en het hydroxy-metaboliet van DMZ en RNZ: 2-hydroxymethyl-l-methyl-5-
nitroimidazole (HMMNI). 
De screening is uitgevoerd met behulp van HPLC-UV. Voor alle analyten werd een detectiegrens 
van 0,5 ug/kg verkregen. De screeningsresultaten wezen uit, dat drie monsters verdacht waren 
op HMMNI en/of MNZ en DMZ. 
De screeningsresultaten zijn bevestigd met behulp van LC-MS/MS. De bevestigingsmethode is 
tevens gebruikt voor de kwantificering van de gehaltes. De screeningsresultaten konden 
bevestigd worden met uitzondering van DMZ in monster 2001-521. De bevestiging duidde net als 
de screening op de aanwezigheid van DMZ in een lage hoeveelheid, maar het signaal van het 
laagste diagnostische ion was onvoldoende voor bevestiging. 
1 INTRODUCTION 
In the framework of the nitroimidazole interlaboratory study 03/01, organised by BGW Berlin in 
its position of Community Reference Laboratory (CRU, for participation of NRL's, four muscle 
samples were analysed for the presence of: dimetridazole (DMZ), ronidazole (RNZ), metronidazole 
(MNZ) and the hydroxy-metabolite of ronidazole and dimetridazole: 2-hydroxymethyl-l-methyl-5-
nitroimidazole (HMMNI). Ipronidazole was not included in the method of analysis. 
The nitroimidazoles are banned substances. The analytical approach for banned substances, in 
contrast to registered ones, has to focus on detecting and identifying the analyte at a level as low 
as possible. 
The muscle samples were first screened for the presence of the above mentioned 
nitroimidazoles. The screening results were used to determine the amount present in the 
interlaboratory study samples. Subsequently, the suspect samples were re-analysed by LC-MS/iyiS 
for confirmation of identity of the analytes and for a more precise determination of the amount 
present. This report describes the analytical procedures for screening and confirmation and the 
results of the interlaboratory study are reported. 
2 EXPERIMENTAL 
2.1 Materials 
All solvents and reagents used were of analytical grade or better. All chemicals were obtained 
from Merck (Darmstadt, Germany). Dimetridazole, ronidazole and metronidazole reference 
standards were obtained from Sigma (St. Louis, MO, USA). 2-hydroxymethyl-l-methyl-5-
nitroimidazole, d3-dimetridazole (d3-DMZ) and d3-ronidazole (d3-RNZ) were obtained from RIVM 
(Bilthoven, The Netherlands). The ultrafilters used had a molecular weight cut-off (MWCO) of 30 
kDa and were obtained from Millipore (Bedford, MA, USA). Oasis HLB® was used as adsorbens for 
the concentration column and was obtained from Waters (Milford, MA, USA). An Alltech (Deerfield, 
IL, USA) Alltima CI8 column (L=15 cm, ID=3.2 mm) was used to establish the separation. 
Lyophilised porcine muscle samples were received in a frozen condition from BGW Berlin and 
were coded: 2001J64, 2001.346, 2001_416 and 2001.521. 
2.2 Sample preparation 
Blank porcine muscle for the preparation of QC samples, was thoroughly minced and 
homogenised. An aliquot of 5 g was taken and transferred to a stomacher bag. 
An aliquot of 1.3 g of the lyophilised porcine muscle samples corresponding to 5 g of fresh 
tissue, was transferred to a stomacher bag and was first reconstituted with water, taking into 
account that the average loss of water was 73%, as specified by BGW. 
Internal standard was added to all samples and QC samples at a level of 1 ug/kg. The samples 
were thoroughly mixed. After 30 min, 10 ml water was added to the samples in the stomacher 
bag and the muscle homogenate was extracted in the stomacher apparatus during 3 minutes. The 
content of the stomacher bag was transferred to a centrifuge tube and centrifuged (15000 g, 15 
min). The supernatant was filtered successively over a 5 urn and a 0.45 urn filter and a 30 kDa 
ultrafilter (UF). The ultrafiltrate was used for the analysis without further purification [1]. 
2.3 Screening analysis 
The screening analysis was carried out with UV detection. 
A Gilson (Villiers-le-Bel, France) 232 autosampler equipped with a 401 dilutor was used. A 
preconcentration column (L=1.0 cm, ID=2 mm) home-packed with Oasis HLB®-material replaced 
the sample loop. The precolumn was loaded by means of direct transfer of the sample by the 
dilutor unit. This permits loading of volumes of several millilitres. Exactly one ml of standard or 
ultrafiltrate was injected on the preconcentration column. 
The chromatographic separation was established on an Alltech C18 (L=15 cm, ID=3,2 mm) 
column using isocratic elution with an eluent consisting of 15% acetonitril in ammonium acetate 
buffer (10 mM, pH=3,5) at a flow rate of 0,4 ml/min. Detection was carried out with an Applied 
Biosystems UV-detector, model 785 A (X=320 nm). 
Calibration was carried out using calibrants in matrix at a level of 2.0; 4.0; 8.0 and 15.0 ugAg 
(referring to fresh tissue) for all analytes. Those calibrants were prepared by fortifying blank 
muscle before the clean-up procedure and were treated identical to the unknown samples. 
2.4 Confirmatory analysis 
The 232 autosampler used for the screening analysis was also used for the confirmatory analysis 
to facilitate the use of the same procedure of large volume injection and column switching. The 
chromatographic separation was established on the same Alltech Alltima C18 (L=15 cm, ID=3.2 
mm) column, however, now gradient elution was used (Table 1). 
Table 1: Gradient used for confirmatory analysis 
Time % 5 mM formic acid % methanol Flow rate (ml/min) 
(min) 
0 
5 
8 
9 
15 
100 
10 
10 
100 
100 
0 
90 
90 
0 
0 
0.4 
0.4 
0.4 
0.4 
0.4 
The column was connected via a 1:1 splitting device to a Micromass (Manchester, UK) Quattro 
Ultima triple quadrupole mass spectrometer equipped with an electrospray ionisation (ESI) 
interface. 
The mass spectrometer was operated in multiple reaction monitoring mode (MRM) recording two 
product ions characteristic for the analytes (Table 2). 
Table 2: Instrumental settings and diagnostic ions, the most abundant product ion is underlined 
Compound 
DMZ 
d3-DMZ 
HMMNI 
MNZ 
RNZ 
drRNZ 
Precursor 
142 
145 
158 
172 
201 
204 
ion (m/z) Product 
25 
96 
99 
140 
55 
12a 
82 
140 
55 
143 
ion (m/z) Dwell time (s) 
0.2 
0.2 
0.2 
0.2 
0.2 
0.2 
0.2 
0.2 
0.2 
0.2 
Collision energy (eV) 
25 
25 
25 
15 
15 
20 
20 
17 
17 
17 
The signal of the most abundant product ion was used for quantitative determination, while the 
other product ion was included for confirmatory purposes. d3-DMZ was used as an internal 
standard for the quantification of DMZ. d3-RNZ was used as internal standard for the quantification 
of RNZ. For MNZ and HMMNI, d3-RNZ was chosen as internal standard, because these analytes 
elute at about the same retention time. 
Calibration was carried out using calibrants in matrix at a level of 0.1; 0.5; 1.0; 2.0 and 5.0 
ug/kg (referring to fresh tissue) or all analytes. Those calibrants were prepared by fortifying blank 
muscle and were treated identical to the unknown samples. 
3 RESULTS AND DISCUSSION 
3.1 Screening analysis 
For the screening, a single analysis of the unknown muscle samples was carried out. 
Figure 1 presents the relation between concentration and response for the matrix calibrants. 
It is clear that there is an almost perfect linear relation (coefficient of correlation ranging from 
0,996 to 0,999) between the response factor (Area) and the fortification level. This points out that 
the analytical procedure is performing satisfactory. 
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Figure 1: Plot of the response factor of HMMNI+MNZ h), RNZ M and DMZ (A) (UV 320 nm) 
versus fortification level of blank porcine muscle. 
MNZ and HMMNI cannot be distinguished in the screening analysis, because these analytes co-
elute under the above mentioned chromatographic conditions. No effort was made to achieve a 
better separation of these analytes, because, if the sample is suspected to contain HMMNI or 
MNZ, the identity of the analyte is always confirmed by LC-MS/MS. HMMNI and MNZ can readily 
be distinguished by LC-MS/MS. A typical chromatogram of the screening analysis of a blank 
muscle fortified at 2.0 pgAg is presented in annex I. 
The recovery was determined by comparing the fortified muscle samples to the standard aqueous 
solutions. The average recovery of the analytes in the range of 2 to 15 ug/kg varies from 86 to 
108 %. 
The limit of detection (LOD) and the limit of quantification (LOQ) can be estimated based on the 
chromatograms of the matrix-calibrants. The LOD is estimated at 0.5 ugAg and the LOQ at 1.0 
ugAg for all analytes. The fresh muscle samples used for the preparation of the QC's showed a 
considerably lower background signal and less interfering peaks than the muscle lyophilates 
supplied in the framework of this interlaboratory study. Comparison of the chromatograms in 
annex I with those in annex II clearly illustrates this phenomenon. Consequently, actual detection 
limits in the lyophilates are slightly higher. 
A chromatogram of each of the interlaboratory study samples is presented in annex II. 
The results of the screening analysis are presented in Table 3. 
Table 3: Screening results for the samples 
Sample 
2001.164 
2001.346 
2001.416 
2001.521 
DMZ RNZ 
2 
-
2 
1 * -
of the interlaboratory study fag/kg) 
MNZ/HMMNI 
16 
-
15 
20 
It was concluded that samples 2001.164, 2001.416 and 2001.521 are suspected to contain 
DMZ and either HMMNI or MNZ. RNZ was not found in the samples. Sample 346 was concluded to 
be negative for the targeted analytes. 
3.2 Confirmatory analysis 
LC-MS/MS was used for the confirmation of the identity of the analytes and for a more precise 
quantitative determination of the amounts present. A duplicate analysis was carried out for all the 
unknown muscle samples. 
Figure 2 presents the relation between concentration and relative response for the matrix 
calibants. 
There is a perfect linear relation (coefficient of correlation is 1,000) between the response factor 
and the fortification level for all analytes. This points out that the confirmatory LC-MS/MS analysis 
procedure is very suitable for the quantitative determination. 
2 4 
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Figure 2: Plotof the response factors of HMMNI (*), MNZ(v), RNZ M and DMZ (s) 
(LC-MS/MS) versus fortification level of blank porcine muscle. 
i 
A chromatogram of a blank muscle fortified at 1.0 ugAg with the targeted nitroimidazoles is 
presented in annex III. The recovery was determined by comparing the blank muscle samples 
fortified before the UF-clean-up to the blank muscle samples fortified after the UF-clean-up. The 
recovery of the analytes varied from 96 to 107 %.These results are in close agreement with the 
results of the screening analysis. 
The limit of detection (LOD) and the limit of quantification (LOQ) were estimated from the 
chromatograms of the matrix calibrants and are presented in table 4. 
Table 4: Limit of detection and limit of quantification using MS/MS 
detection (usAsin fresh muscle) 
Analvte LOP LOQ 
HMMNI 0.25 0.5 
MNZ 0.1 0.2 
RNZ 0.25 0.5 
DMZ 0,1 Q.2 
For RNZ, DMZ and MNZ the most abundant product ion is used for the quantitative analysis to 
obtain a low LOD. RNZ has a higher LOD and LOQ because the intensity of the most abundant 
diagnostic ion is not as high as for DMZ and MNZ. 
Confirmation was carried out using two product ions. MNZ and DMZ can be confirmed at very low 
levels (0.2 ugAg in muscle). RNZ can be confirmed at levels slightly higher than for OMZ and 
MNZ, because the intensity of the second most abundant ion is less (lower relative abundance) 
(Annex IV). 
For HMMNI, the blank showed an interference in the trace of the most abundant product ion. 
This is not surprising since it represents the loss of water from the protonated molecule which is 
not a very characteristic transition. Unfortunately, however, these small molecules exhibit only few 
fragments upon CID and, hence, the choice of diagnostic ions is limited. 
i i 
Therefore, quantification is carried out based on the second-most abundant product ion (m/z=55). 
A consequence is that confirmation cannot be carried out at the same low levels as for DMZ and 
MNZ. However, detection is readily achievable at 0.25 ugAg-
The sensitivity of the confirmatory method (MS/MS) is better than the sensitivity of the screening 
method (UV) and due to its selectivity, provides cleaner chromatograms with fewer interfering 
peaks. Therefore and because of the availability of isotope-labelled analogues, the LC-MS/MS data 
are much better suited for quantification. 
One chromatogram of each interlaboratory study sample is presented in annex V. 
The results of the quantitative analysis using MS/MS detection are presented in table 5. 
The presented values are the average of two separate analyses of the unknown samples. The 
separate results are quite consistent and are presented in the result forms (Annex VI). 
Table 5: Quantitative results for nitroimidazole drugs obtained'byLC-MS/MS 
Sample 
2001.164 
2001.346 
2001.416 
2001.521 
DMZ (ugAg) RNZ(URAR) MNZ (ugAg) HMMNI (ugAg) 
1.3 - - 17.7 
. 
1.3 - - 17.0 
0.1 - 28.7 
The relative abundance of the diagnostic ions was found to be identical to the corresponding 
abundance in the standards. The average relative abundance of the diagnostic ions of the matrix 
calibrants is presented in table 6. The spectra of the four analytes, obtained in standard solutions, 
are presented in annex IV. 
Table 6: Average (n=5) relative abundance of the diagnostic ions of the targeted analytes. 
Analyte 
HMMNI 
MNZ 
RNZ 
DMZ 
Relative abundance (%) 
10.4 
68.2 
10.4 
63.7 
RSD (%) 
* 
9.8 
19.1 
9.6 
* not determined because of interfering compound in one of the ion traces 
Experiments indicate that the relative abundance of HMMNI depends on the amount present in the 
sample at low concentrations (<2.0 ugAg). This is a result of the presence of the interference in 
the trace of the most abundant product ion. Confirmation below 2.0 ugAg is therefore 
troublesome. The average relative abundance for amounts of HMMNI greater than 2 ugAg in 
muscle is presented in table 6. 
For RNZ a low abundance of one of the diagnostic ions was obtained and consequently a higher 
RSD was recorded. For confirmation of low amounts of RNZ, this may pose a problem. 
Confirmation was carried out in accordance with the EU criteria [2]. 
The results of the confirmatory analysis of the interlaboratory study samples are presented in 
table 7. 
12 
Table 7: Confirmatory results of nitroimidazole drugs in lyophilised porcine muscle 
Sample 
2001_164 
2001.164 
2001,416 
2001_416 
2001_521 
2001_521 
Analyte 
HMMNI 
DMZ 
HMMNI 
DMZ 
MNZ 
DMZ 
Screening 
result (ug/kg) 
16 
2 
15 
2 
20 
1 
MS/MS result 
(ug/kg) 
17.7 
1.3 
17.0 
1.2 
28.7 
0.1 
Relative 
abundance 
(r.a.) 
12.1% 
54.9% 
10.6% 
52.2% 
69.3% 
0 
Deviation from 
average r.a. 
16.3% 
13.8% 
1.9% 
18.1% 
1.6% 
Maximum allowed 
dif. of r.a. 
30% 
20% 
30% 
20% 
20% 
[2] 
Confirmation 
POS 
POS 
POS 
POS 
POS 
NEG 
Table 7 shows that the identity of all the analytes found in the screening could be confirmed, 
except for DMZ in sample 2001_521. The suspected presence of DMZ in this sample at LOD level 
was also demonstrated by LC-MS/MS, but the signal of the second-most abundant product ion 
(m/z=95) was lower than S/N=3. Therefore DMZ could not be confirmed in this sample. 
In accordance with the results of the screening analysis, the confirmatory analysis indicated that 
sample 2001_346 was negative for the targeted nitroimidazoles. 
The amount of the analytes present in the unknown samples determined by LC-UV compare quite 
well with the amounts determined by LC-MS/MS. Both are reported in the result forms (Annex VI). 
4 CONCLUSION 
Four samples of lyophilised muscle were analysed for the presence of nitroimidazoles in the 
framework of an interlaboratory study organised by the BGW, Berlin. 
The screening indicated the presence of HMMNI and/or MNZ and DMZ in three of the four 
samples. The screening results were confirmed by LC-MS/MS according to EU criteria [2]. HMMNI 
and MNZ could be readily distinguished in the confirmatory analysis. The amounts present 
determined during the screening analysis compared well with the amount determined by the 
confirmatory analysis. 
LITERATURE 
[1] J.A. van Rhijn, B.J.A. Berendsen, J.J.P. Lasaroms and H.J. Keukens, Confirmatory analysis of 
residues of dimetridazole in muscle by LC-MS. In: Proceedings of the Euroresidue IV 
conference (Edited by: L.A> van Ginkel and A. Ruiter), 2, (2000), 913-919. 
[2] Final Draft Version of the Revision of EC Directive 93/256/EC, SANCO/1805/2000, version 
1, December, 12,2000. 
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Annex I: Screening analysis 
Chromatogram of a blank muscle fortified at 2.0 ug/kg 
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Annex II: Screening analysis 
Chromatograms of interlaboratory study samples 
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Sample 2001.346, no nitroimidazoles detected 
Sample 2001.416,2 pg/kg DMZ, 16 pg/kg HMMNI/MNZ 
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Sample 2001.521,1 Mg/kg DMZ, 20 pg/kg HMMNI/MNZ 
Annex III: Confirmatory analysis 
Chromatogram blank muscle fortified at 1.0 ug/kg 
Blank muscle fortified at 1.0 ug/kg 
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Annex IV: Confirmatory analysis 
CID Spectra of targeted nitroimidazoles 
a: ronidazole, precursor: m/z=201 b: metronidazole, precursor: m/z=172 
10Oi 140.1 
552 
0-
112.) 
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100 120 140 
158.1 
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142.1 
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100 120 140 180 200 
im/z 
C: 2-hydroxymethyl-l-methyl-5-nitroimidazoîe, 
precursor: m/z=158 
d." dimetridazole, precursor: m/z=142 
Annex V: Confirmatory analysis 
Chromatograms of interlaboratory study samples 
a. sample 2001_164, 1.3 (JgAg DMZ, 17.7 pg/kg HMMNI 
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Annex VI: result forms BGW 
1 METHOD DESCRIPTION 
2 
3 
4 
5 
6 METHOD DESCRIPTION 
7 
8 
9 
10 
SCREENING ANALYSIS 
RESULT FORM Sample number 2001_164 
RESULT FORM Sample number 2001_346 
RESULT FORM Sample number 2001_416 
RESULT FORM Sample number 2001_521 
CONFIRMATORY ANALYSIS 
RESULT FORM Sample number 2001_164 
RESULT FORM Sample number 2001_346 
RESULT FORM Sample number 2001_416 
RESULT FORM Sample number 2001_521 
11 QUALITY ASSURANCE MEASURES CONFIRMATORY ANALYSIS 
Participant : RIKILT 
Lab.-Code : 27 
METHOD DESCRIPTION 
SCREENING ANALYSIS 
Short description of the screening method / equipment 
yes D Pre-treatment of the sample: 
Clean-up: 
Derivatisation: 
Measurement method: 
Hydrolysis 
how? 
no H 
liquid/liquid D solvent: 
SPE D phase: solvent: 
other: Extraction (water), ultrafiltration, in-line SPE (Oasis HLB®) 
GC 
Detection method: 
yes D 
if yes, reagent: 
D 
HPLC H 
TLC • 
other: 
MS • 
DAD • 
UV QQ 
other: 
no H 
Reference: 
Which nitroimidazoles can be detected with this screening method? What are the limits of detection for 
these nitroimidazoles in this matrix ? 
Nitroimidazoles 
2-Hydroxymethyl-l-methyl-5-nitroimidazole(HMMNI) 
Metronidazole (MNZ) 
Ronidazole (RNZ) 
Dimetridazole (DMZ) 
limit of detection* [ug/kg] 
0.5 
0.5 
0.5 
0.5 
* fresh tissue 
Remarks: HMMNI and MNZ are co-eluting analytes. Therefore, the screening analysis does not distinguish 
MNZ and HMMNI. 
Participant 
Lab.-Code 
: RIKILT 
: 27 
Sample number : 2001.164 
RESULT FORM 
SCREENING ANALYSIS 
The screening results of the above mentioned sample were positive for the following nitroimidazoles: 
{To remind you again, only one sample preparation per sample was requested. If parallel analyses were 
carried out, please report every individual result and no mean valued): 
Detected 
Nitroimidazoles 
HMMNI/MNZ 
DMZ 
1 Nature of the screening results 
semi-
estimated quantitative quantitative 
-J 3 J 
1 
X 
X 
Concentration* 
tugAg] 
16» 
2 
* fresh tissue 
EH No nitroimidazoles were detected in the above mentioned sample. 
What quality assurance measures were taken to avoid false negative screening results? 
A blank muscle sample was extracted and analysed under similar conditions to the unknown samples. 
Blank muscle samples were fortified at four different levels in the range of 2 to 15 ugAg. 
Remarks: 
1) The screening method cannot distinguish between HMMNI and MNZ. 
Participant 
Lab.-Code 
: RIKILT 
: 27 
Sample number : 200i_346 
RESULT FORM 
SCREENING ANALYSIS 
The screening results of the above mentioned sample were positive for the following nitroimidazoles: 
( 7b» remind you again, only one sample preparation per sample was requested. If parallel analyses were 
carried out, please report every individual result and no mean valued): 
Detected 
Nitroimidazoles 
Nature of the screening results 
Semi-
estimated Quantitative quantitative 
Concentration* 
tugAg] 
1 
* fresh tissue 
PH No nitroimidazoles were detected in the above mentioned sample. 
What quality assurance measures were taken to avoid false negative screening results? 
A blank muscle sample was extracted and analysed under similar conditions to the unknown samples. 
Blank muscle samples were fortified at four different levels in the range of 2 to 15 ugAg. 
Remarks: 
Participant 
Lab.-Code 
: RIKILT 
: 27 
Sample number : 2001_416 
RESULT FORM 
SCREENING ANALYSIS 
The screening results of the above mentioned sample were positive for the following nitroimidazoles: 
( To remind you again, only one sample preparation per sample was requested. If parallel analyses were 
carried out, please report every individual result and no mean valued): 
Detected 
Nitroimidazoles 
HMMNI/MNZ 
DMZ 
Nature of the screening results 
semi-
estimated quantitative quantitative 
L L 
... 
x L 
X 
1 
1 J 1 3 
Concentration* 
(pgAgl 
15» 
2 
* fresh tissue 
O No nitroimidazoles were detected in the above mentioned sample. 
What quality assurance measures were taken to avoid false negative screening results? 
A blank muscle sample was extracted and analysed under similar conditions to the unknown samples. 
Blank muscle samples were fortified at four different levels in the range of 2 to 15 ugAg. 
Remarks: 
1) The screening method cannot distinguish between HMMNI and MNZ. 
Participant 
Lab.-Code 
: RIKILT 
: 27 
Sample number : 2001,521 
RESULT FORM 
SCREENING ANALYSIS 
The screening results of the above mentioned sample were positive for the following nitroimidazoles: 
( To remind you again, only one sample preparation per sample was requested. If parallel analyses were 
carried out, please report every individual result and no mean valued) : 
Detected 
Nitroimidazoles 
HMMNI/MNZ 
DMZ 
Nature of the screening results 
semi-
estimated quantitative quantitative 
X 
X 
Concentration* 
[ugAg] 
201' 
1 
* fresh tissue 
I I No nitroimidazoles were detected in the above mentioned sample. 
What quality assurance measures were taken to avoid false negative screening results? 
A blank muscle sample was extracted and analysed under similar conditions to the unknown samples. 
Blank muscle samples were fortified at four different levels in the range of 2 to 15 ugAg. 
Remarks: 
1) The screening method cannot distinguish between HMMNI and MNZ. 
Participant : RIKILT 
Lab.-Code : 27 
METHOD DESCRIPTION 
CONFIRMATORY ANALYSIS 
Short description of the confirmatory method / equipment 
yes • no Pre-treatment of the sample: 
Clean-up: 
Derivatisation: 
Measurement method: GC 
Detection method: 
Hydrolysis 
how? 
liquid/liquid 
SPE 
other: Extracts 
yes 
if yes, 
D 
HPLC 
TLC 
other: 
MS 
DAD 
UV 
other: 
D 
reagent: 
13 
D 
D 
D 
CS 
• solvent: 
Q phase: solvent: 
tion (water), ultrafiltration, in-line SPE (Oasis HLB®) 
no m 
Reference: 
Which nitroimidazoles are detected by this confirmatory method ? What are the limits of detection, limits of 
determination and recovery rates for these nitroimidazoles in this matrix? 
Nitroimidazoles 
HMMNI 
MNZ 
RNZ 
DMZ 
limit of detection* 
I U E A K ) 
0.25 
0.1 
0.25 
0.1 
•fresh tissue 
limit of determination* 
(ug/kg) 
0.5 
0.2 
0.5 
0.2 
recovery rate 
95 
104 
107 
95 
1 
Remarks: 
Participant 
Lab.-Code 
: RIKILT 
: 27 
Sample number : 2001_164 
RESULT FORM 
CONFIRMATORY ANALYSIS 
The following nitroimidazoles were confirmed by the described method in the above mentioned sample: 
( To remind you again, only one sample preparation per sample was requested. If parallel analyses were 
carried out, please report every individual result and no mean value&Y. 
Confirmed 
nitroimidazoles 
HMMNI 
DMZ 
Number of 
parallel analyses 
2 
2 
Concentration* [ug/kg] 
17.7 
17.7 
1.3 
1.3 
* fresh tissue 
Recovery correction was carried out: " yes H no D 
Note: The results are taken over into the evaluation without any further correction ! 
O The presence of nitroimidazoles could not be confirmed in the above mentioned sample. 
Remarks: 
11
 Recovery correction was intrinsically made by applying isotope dilution. No further correction was made. 
Participant 
Lab.-Code 
RIKILT 
: 27 
Sample number : 2001,346 
RESULT FORM 
CONFIRMATORY ANALYSIS 
The following nitroimidazoles were confirmed by the described method in the above mentioned sample: 
( To remind you again, only one sample preparation per sample was requested. If parallel analyses were 
carried out, please report every individual result and no mean valued): 
Confirmed 
nitroimidazoles 
Number of 
parallel analyses Concentration* fjig/kg] 
i i 
* fresh tissue 
Recovery correction was carried out: yes • no • 
Note: The results are taken over into the evaluation without any further correction ! 
E The presence of nitroimidazoles could not be confirmed in the above mentioned sample. 
Remarks: 
Participant 
Lab.-Code 
: RIKILT 
: 27 
Sample number : 2001_416 
RESULT FORM 
CONFIRMATORY ANALYSIS 
The following nitroimidazoles were confirmed by the described method in the above mentioned sample: 
( To remind you again, only one sample preparation per sample was requested. If parallel analyses were 
carried out, please report every individual resuit and no mean valued) : 
Confirmed 
nitroimidazoles 
HMMNI 
DMZ 
Number of 
parallel analyses 
2 
2 
Concentration* [ug/kg] 
17.2 
15.7 
1.1 
1.2 
* fresh tissue 
Recovery correction was carried out: " yes EG no G 
Note: The results are taken over into the evaluation without any further correction ! 
D The presence of nitroimidazoles could not be confirmed in the above mentioned sample. 
Remarks: 
"Recovery correction was intrinsically made by applying isotope dilution. No further correction was made. 
Participant 
Lab.-Code 
Sample number 
: RIKILT 
: 27 
: 2001_521 
RESULT FORM 
CONFIRMATORY ANALYSIS 
The following nitroimidazoles were confirmed by the described method in the above mentioned sample: 
(To remind you again, only one sample preparation per sample was requested. If parallel analyses were 
carried out, please report every individual result and no mean valued): 
Confirmed 
nitroimidazoles 
MNZ 
1 Number of 
parallel analyses 
2 
Concentration* [ug/kg] 
26.0 
31.4 
j 
_ 
* fresh tissue 
Recovery correction was carried out: " yes E no D 
Note: The results are taken over into the evaluation without any further correction ! 
D The presence of nitroimidazoles could not be confirmed in the above mentioned sample. 
Remarks: DMZ was detected during the confirmatory analysis. The amount of DMZ was quantified at 0,1 
ug/kg in muscle. The presence of DMZ could not be confirmed in accordance with EU regulations. 
"Recovery correction was intrinsically made by applying isotope dilution. No further correction was made. 
Participant 
Lab.-Code 
: RIKILT 
: 27 
QUALITY ASSURANCE MEASURES 
CONFIRMATORY ANALYSIS 
Which criteria were applied to identify the nitroimidazoles? 
The used method complies with EU regulations concerning confirmatory analysis of banned substances: 
Draft revision of Commission Decision 93/256/EC, May 1999. 
Which quality assurance measures were taken to avoid false positive and false negative results? 
A blank muscle sample was extracted and analysed under similar conditions to the unknown samples. 
Blank muscle samples were fortified at five different levels in the range 1 to 5 ug/kg-
Which quality assurance measures were taken to ensure that the analytical system was under statistical 
control? 
A simple test is performed every week, to make sure that the analytical system is working properly. 
Please fill in the following table and indicate all nitroimidazoles confirmed and quantified in the samples: 
confirmed 
nitroimidazoles 
DMZ 
MNZ 
HMMNI 
Number of 
Calibration 
points 
5 
5 
4 
concentration range 
of the calibration [ug/kg] 
0.1-5 
0.1-5 
0.5-5 
correlation 
coefficient 
0.999 
0.999 
0.999 
Remarks: 
